Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
On September 13, 2026, Gland Pharma's Board approved the acquisition of 100% equity of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd for a cash consideration of USD 5,01,208. Gland Pharma USA Inc. is a step-down wholly-owned subsidiary. The company also approved the grant of 590,249 employee stock options to 124 employees under the ESOP 2025 scheme, with exercise prices of INR 1,461.15 and INR 1, vesting over three years starting September 13, 2027. Additionally, 44,193 equity shares were allotted on the exercise of ESOPs.
As of September 18, 2026, Gland Pharma has shown varied returns across different timeframes. The year-to-date (YTD) return is 0.73, and the return over the last 6 months is 0.78. The stock has also seen a return of 0.34 over the last 3 months and 0.47 over the last year. Returns over shorter periods include 0.04 for 1 month, 0.01 for 5 days, and 0.02 for 10 days and 1 day.
On a daily timeframe, Gland Pharma's technical indicators suggest a bullish trend. The Supertrend is at 2709.41, indicating bullishness. The Exponential Moving Average (EMA) 20 is at 2887.87 and the Simple Moving Average (SMA) 20 is at 2900.03, both above the closing price of 2961.9. The EMA 50 is at 2736.37 and the SMA 50 is at 2723.95. The Average Directional Index (ADX) is 32.15, suggesting a strong trend. On a monthly timeframe, the Supertrend is at 1976.35, also indicating a bullish trend, with the EMA 20 at 2090.47 and SMA 20 at 1975.86.
As of September 18, 2026, the nearest support level is at 2959.23, which is 0.09% below the current price. Other support levels are identified at 2889.67, 2838.23, and 2789.55. The nearest resistance level is at 3010.67, which is 1.65% above the current price. Additional resistance levels are noted at 3040.9 and 3080.23.
As of 18 Sept 2026, 03:30 pm
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Primary driver: Price swings are higher than typical
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Upward price movement of 2.96 standard deviations recorded on 2026-07-29.
Unusual market activity that may warrant review of the underlying price, volume, or news context.
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹1,800.27 crore | ₹1,742.79 crore | ₹1,695.36 crore | ₹1,486.88 crore | ₹1,505.62 crore |
| Expenses | PEAK₹1,426.52 crore | ₹1,348.46 crore | ₹1,372.06 crore | ₹1,287.12 crore | ₹1,250.41 crore |
| Profit Before Exceptional Items And Tax | ₹434.98 crore | PEAK₹505.80 crore | ₹386.47 crore | ₹283.92 crore | ₹312.74 crore |
| Profit Before Tax | ₹434.98 crore | PEAK₹505.80 crore | ₹362.13 crore | ₹283.92 crore | ₹312.74 crore |
| Tax Expense | ₹118.02 crore | PEAK₹139.12 crore | ₹100.65 crore | ₹100.23 crore | ₹97.26 crore |
| Profit Loss For Period From Continuing Operations | ₹316.96 crore | PEAK₹366.68 crore | ₹261.48 crore | ₹183.68 crore | ₹215.48 crore |
Gland Pharma’s revenue increased to ₹1,800.27 crore in Q1 FY2026-27, up 3.3% from the previous quarter and 19.6% from the same quarter last year. Net profit, however, fell 13.6% sequentially to ₹316.96 crore, as expenses grew faster than revenue. Compared to the prior year, profit improved 47.1%, supported by revenue growth and a lower expense ratio.
Basic earnings per share (EPS) decreased from ₹22.26 in Q4 to ₹19.23 in Q1, a decline of 13.6%. Year-over-year, EPS increased from ₹13.08 to ₹19.23, a 47.1% rise. Diluted EPS followed the same pattern, moving from ₹22.23 to ₹19.22 sequentially. The EPS movements align directly with the changes in net profit.
Exchange disclosures and regulatory announcements for Gland Pharma.
Gland Pharma Limited has informed the Exchange about Board comments on fines levied by the Exchanges |SUBJECT: General Updates
On September 13, 2026, Gland Pharma's ESOP Compensation Committee approved the grant of 590,249 employee stock options to 124 employees under the ESOP 2025 scheme. The grant includes 389,564 options at an exercise price of INR 1,461.15 (50% of the closing price on September 11, 2026) and 200,685 options at INR 1 (face value). These options follow a three-year vesting schedule with 34% vesting on September 13, 2027, and 33% each on September 13, 2028, and 2029, exercisable within two years of vesting.
Gland Pharma Limited has informed the Exchange about Allotment of 44,193 Equity Shares on exercise of ESOPs |SUBJECT: General Updates
Gland Pharma Limited's Board approved the acquisition of 100% equity of Gland Pharma USA Inc. (Gland US) from Gland Pharma International Pte. Ltd for a cash consideration of USD 5,01,208 on September 13, 2026. Gland US, a step-down wholly-owned subsidiary with nil turnover for FY ending March 31, 2026, will become a direct wholly-owned subsidiary to streamline corporate structure, with completion expected by October 31, 2026.
Gland Pharma Limited has informed the Exchange about acquisition of 100% of the equity share capital of Gland Pharma USA Inc. , a wholly-owned step down subsidiary of the Company, from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company |SUBJECT: General Updates
Gland Pharma Limited scheduled analyst and institutional investor meetings for September 16, 2026, with East Bridge Capital; September 17, 2026, with IIFL Capital and Antique Broking; and a group meeting on September 25, 2026, arranged by Nomura. The company secretary confirmed that this schedule is subject to change due to exigencies affecting the investors, analysts, or the company.
Gland Pharma Limited will hold an in-person one-on-one institutional investor meeting with DSP Mutual Fund on September 11, 2026, at 4:30 PM in Hyderabad to discuss the company's outlook.
Recent market and company developments associated with Gland Pharma.
Bulk Deals,Entero Healthcare Solutions,Rentomojo,Karamtara Engineering,Gland Pharma
Powered by Capital Market - Live News
The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction.
Gland Pharma, Fosun, divestment, share sale, CDMO
Gland Pharma Ltd is quoting at Rs 2974.6, up 1.44% on the day as on 12:49 IST on the NSE. The stock is up 58.38% in last one year as compared to a 4.12% jump in NIFTY and a 21.48% jump in the Nifty Pharma index.
Fosun Pharma sold a 4.55 percent stake in Gland Pharma for Rs 2,121.50 crore, reducing its holding to 47.22 percent.
Fosun Pharma, Gland Pharma, Fosun Pharma stake sale, Gland Pharma block deal, Gland Pharma shares, Fosun Pharma Gland Pharma stake, Gland Pharma shareholding, Kotak Mahindra Mutual Fund, Axis Mutual Fund, ICICI Prudential Mutual Fund, Gland Pharma Q1 results, Gland Pharma net profit, Gland Pharma revenue, pharma stocks, block deals, Fosun Pharmaceutical
The transaction marks the second major stake sale by Fosun Pharma in the pharmaceutical company in a little over two years
Comprehensive Section Breakdown for Gland Pharma
Strategic Vision: Manufactures and markets complex generic injectables globally.
• Expertise in pharmaceutical research and development, manufacturing, and marketing of complex injectables.
• Global supply chain reaching over 60 countries, including key regulated markets.
• Capabilities in developing niche products through complex molecule synthesis and diverse delivery systems.
Revenue grew both sequentially and year-over-year. The sequential increase of ₹57.48 crore (3.3%) was smaller than the year-over-year increase of ₹294.65 crore (19.6%). Expenses rose 5.8% sequentially to ₹1,426.52 crore, outpacing the 3.3% revenue growth. As a result, the expense-to-revenue ratio increased from 77.4% in Q4 FY2025-26 to 79.2% in the current quarter. On a year-over-year basis, expenses grew 14.1% while revenue grew 19.6%, so the expense ratio improved from 83.0% in Q1 FY2025-26 to 79.2% in the current quarter.
Profit before tax (PBT) decreased 14.0% sequentially to ₹434.98 crore, and net profit decreased 13.6% to ₹316.96 crore. The sequential decline in profit occurred despite higher revenue, reflecting the faster rise in expenses. The PBT margin fell from 29.0% in Q4 to 24.2% in Q1, and the net profit margin fell from 21.0% to 17.6%. Year-over-year, margins expanded: PBT margin was 20.8% in Q1 FY2025-26 and net profit margin was 14.3%, both lower than the current quarter’s margins. No exceptional items were reported in the current or previous quarter.
Finance costs decreased to ₹4.36 crore from ₹10.03 crore in the previous quarter, a 56.5% decline. This reduction helped partially offset the overall expense growth, though the absolute amount remains small relative to total expenses. Other comprehensive income (OCI) swung from a gain of ₹100.91 crore in Q4 to a loss of ₹26.72 crore in Q1, a negative movement of ₹127.63 crore. This large swing does not affect operating profit but impacts total comprehensive income.
Gland Pharma reported a strong Q1FY27 with revenue up 20% YoY to ₹18,003 Mn and PAT up 47% YoY to ₹3,170 Mn, driven by successful execution of its CDMO strategy and resilient B2B model. Management highlighted growth from recent product launches (e.g., Dalbavancin, Multi-Vitamin) and strong customer demand across diversified product mix. The CDMO business contributed 50% of revenue, growing 20% YoY, while B2B grew 19% YoY. The US market led with 32% YoY growth, supported by volume expansion in Enoxaparin, Vancomycin, and Heparin.
Looking ahead, management expects sustainable long-term growth through a robust CDMO pipeline, including investments in differentiated technologies and capacity expansions. Key growth drivers include a CDMO partnership with a global pharma company (potential ~USD 90-100M annualized revenue from CY2029), a $644M RTU bag portfolio opportunity, and 15 co-development products expected to commercialize in FY28. R&D spending was ₹772 Mn (4% of revenue), focused on complex product development. Risks include volume decline in other core markets (Canada, Australia, NZ down 28% YoY) and reliance on timely tech transfers and approvals.
Gland Pharma’s Q1 FY2026-27 results show significant year-over-year revenue and profit growth, but the sequential decline in profit from the prior quarter marks a shift in momentum. The faster growth in expenses relative to revenue sequentially compressed margins, while the year-over-year comparison shows a lower expense ratio. The large swing in other comprehensive income and the decline in finance costs were non-operating factors. Overall, the quarter demonstrates substantial year-over-year growth, while the sequential cost increase reverses the margin improvement seen in the previous quarter.
Category: Manufacturing
The company is active in sterile injectables, focusing on complex products including NCE-1s, First-to-File products, and 505(b)(2) filings.
Category: Manufacturing
Gland Pharma is active in the oncology therapeutic segment, focusing on complex injectables.
Category: Manufacturing
Gland Pharma is active in the ophthalmic therapeutic segment, focusing on complex injectables.
Core Thesis: Leveraging R&D and manufacturing expertise to provide complex injectable solutions through diverse business models and global partnerships.
• Global Out-Licensing: Partnerships in regulated markets involve expense and profit-sharing for product development, licensing, manufacturing, and supply, covering early and late-stage products. • Technology Transfer: Partners transfer technology for manufacturing, testing, and packaging, with Gland Pharma handling method transfer, validation, scale-up, and dossier support. • Co-marketing in India: Offering generic products to partners to expand their portfolios in the Indian market, utilizing Gland Pharma's R&D and manufacturing capabilities.